Table 5.
Risk group distribution before and after mpMRI of the prostate
| Clinical staging | Relative upward shift by mpMRI | Relative downward shift by mpMRI | mpMRI staging | |
|---|---|---|---|---|
| Low-risk group | 14 (11.5%) | 57.1% | n.a. | 7 (5.7%) |
| Intermediate-risk group | 52 (42.6%) | 30.8% | 0% | 44 (36.1%) |
| High-risk group | 53 (43.4%) | 13.2% | 5.7% | 59 (48.4%) |
| Nodal metastases (cN1) | 3 (2.5%) | 0% | 33.3% | 9 (7.4%) |
| Distant metastases (cM1) | 0 | n.a. | n.a. | 3 (2.5%) |
Risk groups for patients (n = 122) were defined according to the National Comprehensive Cancer Network prostate cancer guidelines based on T stage, serum PSA level and the Gleason score derived from prostate biopsy. n.a. = not available.